2 results
17/Dec/2025
17/Dec/2025
DOI: 10.31744/einstein_journal/2026RC1689
Abstract Breast cancer is one of the most prevalent and heterogeneous cancers worldwide; however, it remains a complex and enigmatic disease. Advances in targeted therapies combined with increasing knowledge about tumor subtypes and molecular profiling have placed precision medicine on the frontier of oncological treatments. The recent classification of certain HER2 tumors as HER2-low, along with emerging evidence from studies using antibody-drug conjugates to target specific tumor profiles, highlights the relevance of this case study. This report describes the treatment […]
Keywords: Breast neoplasms; Immunoconjugates; Molecular targeted therapy; Precision medicine; Receptor, ErbB-2; Trastuzumab deruxtecan
30/Jan/2024
DOI: 10.31744/einstein_journal/2024RW0552
ABSTRACT Introduction Triple-negative breast cancer is an aggressive subtype of breast cancer characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. This phenotype renders triple-negative breast cancer cells refractory to conventional therapies, resulting in poor clinical outcomes and an urgent need for novel therapeutic approaches. Recent studies have implicated dysregulation of the Notch receptor signaling pathway in the development and progression of triple-negative breast cancer. Objective This study aimed to conduct a […]
Keywords: Cell proliferation; MicroRNAs; Molecular targeted therapy; Notch1; Receptors; Signal transduction; Triple-negative breast neoplasms